Clinical trial · Interventional
Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients
A Phase II Randomized, Open-label Study Investigating the Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients
NCT01359735CI-TRIAL-00028333completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study compares HP802-247 versus an antibiotic ointment for healing the wound after Mohs surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-melanoma Skin Cancer | Skin Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bacitracin Ointment | Biological | — | UNRESOLVED |
| HP802-247 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- HP802-247
- description
- allogeneic, growth arrested keratinocytes and fibroblasts: final concentration of 5.0 M cells/mL with a ratio of 1:9 keratinocytes:fibroblasts, applied weekly
- interventionNames
- Biological: HP802-247
- type
- ACTIVE_COMPARATOR
- label
- Bacitracin Ointment
- description
- bacitracin antibiotic ointment
- interventionNames
- Biological: Bacitracin Ointment
Primary outcomes (1)
- measure
- The Primary Efficacy Measure Was the Investigator's Global Assessment of Healing (IGAH).
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Provide informed consent. * Age ≥ 18 years and of either sex. * Type I, II, or III skin as assessed by the Fitzpatrick Scale. * Willing to comply with protocol instructions, including allowing all study assessments. * Scheduled to have head or neck non-melanoma skin cancers removed by Mohs micrographic surgery with final wound size of 8 mm to 20 mm in diameter or with 8 mm to 20 mm long axis if not circular. * Acceptable state of health and nutrition, in the opinion of the Investigator. Exclusion Criteria: * History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, or amphotericin B. * Therapy with blood-thinning agents including aspirin within 14 days of the Baseline Visit (these may be resumed post-surgery). * Subjects with platelet or coagulation disorders. * Therapy with another investigational agent within thirty (30) days of Screening, or during the study. * Current systemic therapy with cytotoxic drugs. * Current therapy with chronic (\> 10 days) oral corticosteroids. * In the opinion of the Investigator the subject has a current life expectancy of less than 1 year.
References
Publications (0)
Data not yet available
No reference posted for this study.